Publications by authors named "E Pasquinucci"
Article Synopsis
- Two patients developed severe hypophosphatemia requiring hospitalization after denosumab treatment for osteoporosis, despite having normal kidney function and no known risk factors.
- Both patients experienced neurological symptoms and severe fatigue, which improved with intravenous phosphate treatment, and they left the hospital with oral phosphate and vitamin D supplements.
- As denosumab use increases, it's important to monitor serum phosphate and related levels regularly, and to consider hypophosphatemia as a potential issue when patients report unexplained fatigue or muscle problems.
Key Points: Patients with AA amyloidosis and age ≥65 years, eGFR <45 ml/min per 1.73 m, and -terminal type-B natriuretic peptide >1000 ng/L and/or type-B natriuretic peptide >130 ng/L at diagnosis have poorer survival. Proteinuria >3.
View Article and Find Full Text PDFIntroduction: Living donor kidney transplant (LDKT) is one of the best therapeutic options for end-stage kidney disease (ESKD). Guidelines identify different estimated glomerular filtration rate (eGFR) thresholds to determine the eligibility of donors. The aim of our study was to evaluate whether pretransplant donor eGFR was associated with kidney function in the recipient.
View Article and Find Full Text PDF